Evidence for TORC1 activation marker as a predictive factor for everolimus efficacy in metastatic breast cancer

Share :
Published: 17 May 2012
Views: 4062
Dr Thomas Bachelot - Centre Leon Berard, Lyon, France

A new analysis may help doctors identify breast cancer patients who will benefit from treatment with the immune suppressant drug everolimus, said French researchers at the 4th IMPAKT Breast Cancer Conference in Brussels, Belgium.

Everolimus is currently used as an immunosuppressant to prevent patients rejecting transplanted organs and in the treatment of renal cell cancer. 

Research is also being conducted into the drug’s use in other cancers, including breast cancer.

Dr Thomas Bachelot, from Centre Leon Berard in Lyon and colleagues analyzed data from the TAMRAD study, published two years ago

Filming Supported by Amgen